Alimera Sciences, Inc. (NASDAQ:ALIM)

CAPS Rating: 2 out of 5

Results 1 - 9 of 9

Recs

1
Member Avatar zzlangerhans (99.79) Submitted: 1/11/2016 8:49:40 AM : Outperform Start Price: $2.51 ALIM Score: -11.11

When these inevitable broad declines come along, I start looking for two kinds of stocks: companies with potential that have been overly punished, and companies which are doomed long-term and haven't been punished enough. I try and green thumb the former and red thumb the latter. I've been an Alimera bear for quite some time, but the stock has now been beaten down enough that I'll hazard an outperform rating ahead of a predicted ramp in Iluvien sales in 2016 once a J code has been granted. I wouldn't use real money to bet that Alimera can achieve positive cash flow from Iluvien based on their optimistic projections, but I'll risk an accuracy point to follow the story in the virtual realm.

Recs

0
Member Avatar rknapton (23.60) Submitted: 7/23/2013 8:12:18 PM : Underperform Start Price: $5.10 ALIM Score: +68.53

Short. Biopharma. $0 Revenues. Consistent share dilution.

Recs

0
Member Avatar rielfireflame (< 20) Submitted: 5/14/2013 12:01:17 AM : Outperform Start Price: $4.00 ALIM Score: -61.45

This stock has been growing over the past few weeks. It seems that the growth is constant and should continue to grow over the next few weeks.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:49:24 PM : Outperform Start Price: $4.23 ALIM Score: -85.74

went up 244% for portefeille.

Recs

0
Member Avatar trockn (< 20) Submitted: 3/10/2012 11:14:03 AM : Outperform Start Price: $4.00 ALIM Score: -82.94

This is a huge need in Ophthalmology patient care. Patients are enduring numerous injections into the eye to decrease edema and the progressive damage it can create. This time-released med will last a long time while decreasing risk and cost to the patient.

Recs

0
Member Avatar Jemabogado (< 20) Submitted: 11/13/2011 4:24:41 PM : Outperform Start Price: $2.03 ALIM Score: -44.85

European approval will help lift it from the basement of FDA rejection!

Recs

0
Member Avatar FUZZYMINKINS (< 20) Submitted: 5/21/2011 10:51:50 AM : Outperform Start Price: $8.42 ALIM Score: -112.86

Diabetes Diabetes Diabetes. americans are unhealthy

Recs

0
Member Avatar TMFBiologyFool (97.59) Submitted: 1/24/2011 1:47:55 PM : Outperform Start Price: $8.90 ALIM Score: -120.23

First FDA rejection was fairly benign. Investors will come back as second decision approaches.

Recs

0
Member Avatar Brent2223 (33.07) Submitted: 12/31/2010 10:51:37 AM : Outperform Start Price: $10.13 ALIM Score: -126.94

oversold on FDA news

Results 1 - 9 of 9

Featured Broker Partners